Literature DB >> 6850612

Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative gastric cancer patients.

T Ochiai, H Sato, H Sato, R Hayashi, T Asano, K Isono, T Suzuki, M Nagata, K Enomoto, Y Gunji, K Okuyama, T Tanaka.   

Abstract

From September 1979 through March 1981, a total of 302 patients with gastric cancer and undergoing gastrectomy at the Department of Surgery at Chiba University Hospital and its 14 affiliated hospitals was studied for clinical effectiveness of immunotherapy with Nocardia rubra cell wall skeleton. The patients were stratified by gross stage of cancer and degree of operative curability. They were then assigned randomly to either chemotherapy group or chemotherapy plus immunotherapy group. Immunotherapy used was intradermal injection of 400 micrograms of N. rubra cell wall skeleton which was given weekly for the first month and monthly thereafter. After the specimen was examined microscopically, the patients were classified by histological stage of cancer and radicality of surgical intervention into curative or noncurative groups. The patients were surveyed for survival period in December 1981. The postoperative survival rate was compared in patients of histologically curative or noncurative resection cases between the two treatment groups. No statistical difference was detected between the groups in age, sex, or operative procedures that might influence the patient's survival. As a result, statistical intergroup difference in survival rates was not seen in patients of the curative group, probably due to a short observation period. However, the intergroup difference in survival rates was statistically significant in patients of the noncurative group (p less than 0.01). These results indicate the adjunctive effect of N. rubra cell wall skeleton as an immunotherapeutic agent in patients undergoing gastrectomy for gastric cancer.

Entities:  

Mesh:

Year:  1983        PMID: 6850612

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Randomized controlled study of postoperative adjuvant immunochemotherapy with Nocardia rubra cell wall skeleton (N-CWS) and Tegafur for gastric carcinoma.

Authors:  S Koyama; A Ozaki; Y Iwasaki; T Sakita; T Osuga; A Watanabe; M Suzuki; T Kawasaki; T Soma; T Tabuchi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Augmented production of colony-stimulating factor in C3H/HeN mice immunized with Nocardia rubra cell wall skeleton.

Authors:  S Hayashi; T Masuno; S Hosoe; I Kawase; M Sakatani; T Ogura; S Kishimoto; Y Yamamura
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

Review 3.  Adjuvant chemotherapy for gastric cancer: current evidence and future challenges.

Authors:  Rosalba Miceli; Gianluca Tomasello; Giacomo Bregni; Maria Di Bartolomeo; Filippo Pietrantonio
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

4.  Effect of Nocardia rubra cell-wall skeleton on cancer prevention in humans.

Authors:  M Yamakido; S Ishioka; S Hozawa; S Matsuzaka; J Yanagida; T Shigenobu; M Otake; Y Nishimoto
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Augmentative effect of Nocardia rubra cell-wall skeleton on the induction of human lymphokine-activated killer (LAK) cells by the production of LAK cell helper factor(s).

Authors:  T Shirasaka; I Kawase; M Okada; M Kitahara; T Ikeda; K Komuta; S Hosoe; S Yokota; T Masuno; S Kishimoto
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  R0 resection in the treatment of gastric cancer: room for improvement.

Authors:  Alberto Biondi; Roberto Persiani; Ferdinando Cananzi; Marco Zoccali; Vincenzo Vigorita; Andrea Tufo; Domenico D'Ugo
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

7.  Anti-tumour activity of Lactobacillus casei on Lewis lung carcinoma and line-10 hepatoma in syngeneic mice and guinea pigs.

Authors:  T Matsuzaki; T Yokokura; I Azuma
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

Review 8.  Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity.

Authors:  Tsukasa Seya; Hiroaki Shime; Yohei Takeda; Megumi Tatematsu; Ken Takashima; Misako Matsumoto
Journal:  Cancer Sci       Date:  2015-11-18       Impact factor: 6.716

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.